Can Mounjaro Cause a Stroke? What the Clinical Evidence Actually Shows

Step 1: Check what the regulator and NHS guidance currently say

The starting point for any question about a medicine's safety profile is the official record. Mounjaro's UK Summary of Product Characteristics, published on the electronic Medicines Compendium, does not list stroke as a recognised adverse reaction. The NHS tirzepatide medicines page catalogues the known side effects in plain language — they are led by gastrointestinal symptoms such as nausea, diarrhoea and constipation, along with headache, dizziness and injection-site reactions. Cerebrovascular events are absent from that list.

Mounjaro also carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring precisely because it is relatively new. If you want a detailed look at how Mounjaro and stroke are discussed in the current evidence, including what real-world monitoring has and has not turned up, that page brings together the key points in one place. Patients and clinicians can report any suspected side effect, including ones not in the leaflet, via the MHRA's Yellow Card scheme.

Worth noting: the NICE technology appraisal for tirzepatide (TA1026) reviewed a substantial body of clinical evidence before recommending the medicine. A cardiovascular safety concern of the magnitude of stroke would have featured prominently in that committee's deliberations. It did not.

Step 2: Understand what the SURMOUNT trials measured, and what they did not

The SURMOUNT clinical programme enrolled thousands of adults over periods of up to 72 weeks. SURMOUNT-1, published in the New England Journal of Medicine, focused on weight reduction in people with obesity and found tirzepatide produced average body-weight reductions of around 20–21% at the highest dose. Cardiovascular events were recorded as part of safety monitoring, but SURMOUNT-1 was not designed or powered to detect differences in stroke rates, that requires a dedicated cardiovascular outcomes trial with a far larger participant pool and longer follow-up.

That trial exists. The SURPASS-CVOT programme is studying tirzepatide's effect on major adverse cardiovascular events, including stroke, in people with type 2 diabetes at elevated cardiovascular risk. Full results from adequately powered cardiovascular outcome trials take years to mature. Until they do, the honest position is that the data are not yet sufficient to conclude that tirzepatide either increases or reduces stroke risk in any specific population, though the directional signals from related GLP-1 medicines are broadly reassuring.

If you want to explore the broader range of questions about what Mounjaro can and cannot cause, our overview of Mounjaro's known effects brings together the current evidence in one place.

Step 3: Put obesity, stroke, and weight loss treatment in context

Obesity is itself a recognised independent risk factor for ischaemic stroke, linked to hypertension, atrial fibrillation, dyslipidaemia and insulin resistance, all pathways that can raise cerebrovascular risk. Clinically meaningful weight loss tends to improve several of these markers. GLP-1 receptor agonists as a class have shown cardiovascular benefit in large outcome trials, most notably semaglutide's SELECT trial, which demonstrated a reduction in major cardiovascular events. Tirzepatide's dual GIP and GLP-1 mechanism is biologically distinct, so those findings do not transfer directly, but they do provide a mechanistic rationale for optimism.

None of this means Mounjaro is appropriate for every person who asks about it, particularly anyone with a history of transient ischaemic attacks or previous stroke. If you have been asking yourself whether Mounjaro can cause strokes, that page works through the clinical reasoning and current data in full, which is a useful read before speaking with a prescriber. Our full tirzepatide guide covers the medicine's licensed uses, eligibility criteria, and the clinical factors that shape those decisions.

Step 4: Recognise symptoms that need emergency care, not reassurance

Whatever medicine you are taking, the symptoms of stroke are a 999 situation. The FAST acronym (Face drooping, Arm weakness, Speech difficulty, Time to call 999) applies without exception. No side-effect question, no pharmacist, and certainly no webpage should stand between you and emergency services if those signs appear.

Separately, there is a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION) that some researchers have examined in relation to GLP-1 medicines. It is not a stroke, but it involves sudden vision changes and warrants immediate medical review. Our page on NAION and tirzepatide covers what is currently known. For a broader look at neurological questions people ask about this medicine, see the evidence on Mounjaro and MS.

If you are already on treatment and have concerns about any symptom, our clinical team is reachable seven days a week, you can reach us via the contact page. For anyone considering starting treatment and wanting to understand the full risk-benefit picture, a free consultation with our prescribers is the right next step. They review every application the same day, as real clinicians, so your questions get a considered answer rather than a standardised response.